Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is projected to reach $11.2 billion by 2030.